Fung 1991.

Methods	Randomised clinical trial
Participants	Country: USA Number randomised: 81 Postrandomisation dropouts: not stated Revised sample size: 81 Average age: 42 years Females: 33 (40.7%) Primary transplantation: 81 (100%) Retransplantation: 0 (0%) HCV: not stated HBV: 0 (0%) Alcoholic cirrhosis: not stated Other causes: not stated Average follow‐up period in months (for all groups): 12 Additional treatment such as antiviral drugs: none stated Important inclusion and exclusion criteria Primary transplantation only: yes Retransplantation only: no HCV only: not stated HBV only: no Alcoholic cirrhosis only: not stated Other causes: not stated Important exclusion criteria: People with cancer People undergoing multiple organ transplantation People with pre‐existing renal failure Active infection Stage 4 coma, defined as unconscious and ventilator dependent Clinically significant heart or lung disease Previous reconstructive or bypass procedures of the liver Technically unsatisfactory operations with poor immediate liver function
Interventions	Participants were randomly assigned to 2 groups. Group 1: cyclosporine A (n = 40). Further details: cyclosporine A: attain 600 to 800 ng/mL. Group 2: tacrolimus (n = 41). Further details: tacrolimus: attain 1 to 5 ng/mL.
Outcomes	The outcomes reported were: mortality, graft loss, adverse events, renal impairment, retransplantation, graft rejection.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Quote: "treatment assignment was determined by a computer program implementing the block randomization technique, to assure that the treatment groups remained reasonably balanced"
Allocation concealment (selection bias)	Low risk	Quote: "a sealed envelope method was implemented. Each envelope contained a single treatment assignment".
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Comment: this information was not available.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Comment: this information was not available.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Comment: this information was not available.
Selective reporting (reporting bias)	Low risk	Comment: no published protocol available; mortality/graft loss and adverse events were reported.
For‐profit bias	Low risk	Quote: "this work was supported by research grant OK 29961 from the National Institutes of Health, Bethesda, Maryland, and the Veterans Administration".
Other bias	Low risk	Comment: no other bias noted.